seed
Stage
About
KyDo Therapeutics GmbH is a preclinical-stage German biotechnology company developing covalent-allosteric small-molecule inhibitors for oncology. Its lead programs target AKT-driven cancers including glioblastoma and are being advanced toward IND-enabling studies following a €4.45M seed round.
Explore KyDo Therapeutics GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.